COMMUNIQUÉS West-GlobeNewswire

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024
26/01/2024
Q3W schedule of CRB-701 (SYS6002) demonstrates a 43% ORR and 71% DCR at predicted therapeutically relevant doses All assessable nectin-4 positive study participants with mUC and cervical cancer treated at or above this [...]
Apellis Announces Negative CHMP Opinion for Pegcetacoplan for GA in the European Union and Plans to Seek Re-Examination of Application
26/01/2024
WALTHAM, Mass., Jan. 26, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted [...]
Pharvaris to Present at the WSAAI Annual Meeting 2024
26/01/2024
ZUG, Switzerland, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, [...]
All necessary regulatory approvals have been obtained for the combination of Novozymes and Chr. Hansen
26/01/2024
January 26, 2024 – Company announcement no. 1 Please see attachment. Contact information Investor Relations Disa Tuominen +45 6038 5826 dkditu@chr-hansen.com Press Relations Sanne Seyer-Hansen +45 6038 6207 dksash@chr- [...]
All necessary regulatory approvals have been obtained for the combination of Novozymes and Chr. Hansen
26/01/2024
Please read the full announcement in PDF Attachment 2024_01_All_Regulatory_Approvals_Obtained
Additional ODM-208/MK-5684 Phase II data presented at ASCO-GU 2024
26/01/2024
ORION CORPORATION PRESS RELEASE 26 JANUARY 2024 at 09.00 EET Additional ODM-208/MK-5684 Phase II data presented at ASCO-GU 2024 Orion presented yesterday at the 2024 ASCO GU Cancers Symposium a poster with additional [...]
ArriVent Announces Pricing of Upsized Initial Public Offering
26/01/2024
NEWTOWN SQUARE, Pa., Jan. 25, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (“ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical [...]
Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock
26/01/2024
SAN MATEO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (“Sagimet”) (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to [...]
Psyence Biomedical Ltd. Approved to List on Nasdaq following Completion of Business Combination Agreement with Newcourt Acquisition Corp
26/01/2024
TORONTO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group"), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing, is [...]
Psyence Biomedical Ltd. Approved to List on Nasdaq following Completion of Business Combination Agreement with Newcourt Acquisition Corp
25/01/2024
TORONTO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (“Psyence Biomed”) is excited to announce the completion of its merger (the “Business Combination”) with Newcourt Acquisition Corp ("Newcourt"), a [...]
ONWARD® ARC Therapy™ Highlighted at 2024 Annual Meeting of the North American Neuromodulation Society (NANS)
25/01/2024
Clinical experience with investigational ARC-EX® Therapy showcased on the main stage and in clinical abstracts during the 2024 NANS Annual Meeting EINDHOVEN, the Netherlands, Jan. 25, 2024 (GLOBE NEWSWIRE) -- ONWARD [...]
Titan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteria
25/01/2024
SOUTH SAN FRANCISCO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) today announced that by letter dated January 24, 2024, the Company was notified by The [...]
CooperCompanies Announces Release Date for First Quarter 2024
25/01/2024
SAN RAMON, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO) today announced it will report first quarter 2024 financial results on Thursday, February 29, 2024, at 4:15 PM ET. Following the release [...]
Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
25/01/2024
Safety and initial efficacy data from Stage 1 expected in the first half of 2024 Dose selection and initiation of Stage 2 to follow in the second half of 2024 NOVATO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx [...]
CVRx Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
25/01/2024
MINNEAPOLIS, Jan. 25, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients [...]
Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations
25/01/2024
Renalys expected to initiate registrational study in the second quarter of 2024 to support potential approval of sparsentan for IgA nephropathy in Japan SAN DIEGO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics [...]
Introducing cutting-edge features to transform the dental experience: PreVu Software unveils AI-powered enhancements for smile simulation software
25/01/2024
FORT LAUDERDALE, FLA, Jan. 25, 2024 (GLOBE NEWSWIRE) -- PreVu Software, a pioneer in dental technology solutions, proudly announces the launch of new, innovative technology that will continue our tradition of delivering [...]
Press Release: Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE)
25/01/2024
Dupixent ® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE) Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children [...]
Communiqué de presse : Dupixent® : premier et seul médicament approuvé par la FDA pour le traitement de l’œsophagite à éosinophiles de l’enfant à partir de 12 mois
25/01/2024
Dupixent ® : premier et seul médicament approuvé par la FDA pour le traitement de l’œsophagite à éosinophiles de l’enfant à partir de 12 mois Approbation fondée sur les résultats de l’essai de phase III EoE KIDS ayant [...]

Pages